Skip to content
Loading your account…

ABT ABBOTT LABORATORIES

NYSEHealth carePharmaceutical PreparationsAbbott Park, ILFY ends December 31

Profitable 5/5: Fiscal years with net income above zero, out of the last five reported.FY2025 10-K filed Feb 20, 2026 (SEC EDGAR)

FY2025 at a glance

Fundamentals from SEC filings, not quotes
Revenue
$44.3BYoYup 5.67%ended Dec 31, 2025
Net income
$6.52B14.7% margin
Diluted EPS
$3.72YoYdown 51.31%
Free cash flow
$7.4B16.7% margin
Cash
$8.52BNet debt $4.41B
Total debt
$12.9BD/E 0.25×
About ABBOTT LABORATORIES

Overview

ABBOTT LABORATORIES (ABT) is listed on NYSE; the SEC classifies it under "Pharmaceutical Preparations".

For fiscal 2025 (ended Dec 31, 2025) it reported revenue of $44.33B, up 5.7% from fiscal 2024.

Net income was $6.52B, a net margin of 14.7%.

At fiscal year end it had total assets of $86.71B and stockholders' equity of $52.13B (60.1% of assets).

Fiscal years shown
FY2016–FY2025 (10 years)
Latest 10-K
Feb 20, 2026
Latest filing
8-KOct 21, 2026
FY2016–FY2025 · annual 10-K

Charts

Revenue and net income

Revenue and net income, fiscal years FY2016 to FY2025.
PeriodRevenueNet incomeNet margin
FY2016$20.9B$1.4B6.7%
FY2017$27.4B$477M1.7%
FY2018$30.6B$2.37B7.7%
FY2019$31.9B$3.69B11.6%
FY2020$34.6B$4.5B13.0%
FY2021$43.1B$7.07B16.4%
FY2022$43.7B$6.93B15.9%
FY2023$40.1B$5.72B14.3%
FY2024$42B$13.4B31.9%
FY2025$44.3B$6.52B14.7%

Gross, operating and net margin

Gross, operating and net margin, fiscal years FY2016 to FY2025.
PeriodGross marginOperating marginNet margin
FY2016—15.3%6.7%
FY2017—6.3%1.7%
FY201858.4%11.9%7.7%
FY201958.5%14.2%11.6%
FY202056.6%15.5%13.0%
FY202157.0%19.6%16.4%
FY202256.1%19.2%15.9%
FY202355.2%16.2%14.3%
FY202455.4%16.3%31.9%
FY202556.4%18.2%14.7%

Diluted EPS

Diluted EPS, fiscal years FY2016 to FY2025.
PeriodEPS (diluted)
FY2016$0.94
FY2017$0.27
FY2018$1.33
FY2019$2.06
FY2020$2.50
FY2021$3.94
FY2022$3.91
FY2023$3.26
FY2024$7.64
FY2025$3.72

Free cash flow vs net income

Free cash flow vs net income, fiscal years FY2016 to FY2025.
PeriodFree cash flowNet income
FY2016$2.08B$1.4B
FY2017$4.44B$477M
FY2018$4.91B$2.37B
FY2019$4.5B$3.69B
FY2020$5.72B$4.5B
FY2021$8.65B$7.07B
FY2022$7.8B$6.93B
FY2023$5.06B$5.72B
FY2024$6.35B$13.4B
FY2025$7.4B$6.52B

Diluted shares

Diluted shares, fiscal years FY2016 to FY2025.
PeriodDiluted shares (weighted)
FY20161.48B
FY20171.75B
FY20181.77B
FY20191.78B
FY20201.79B
FY20211.79B
FY20221.76B
FY20231.75B
FY20241.75B
FY20251.75B

Cash vs total debt

Cash vs total debt, fiscal years FY2016 to FY2025.
PeriodCash & equivalentsTotal debt
FY2016$18.6B$22B
FY2017$9.41B$27.9B
FY2018$3.84B$19.6B
FY2019$3.86B$18.1B
FY2020$6.84B$18.7B
FY2021$9.8B$18.1B
FY2022$9.88B$16.8B
FY2023$6.9B$14.7B
FY2024$7.62B$14.1B
FY2025$8.52B$12.9B

Each bar is one fiscal year as reported in its 10-K; bars below the zero line are negative and gaps are years not reported. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

FY2025 · 5-year trend

Ratios

Profitability

Gross margin
56.4%
Operating margin
18.2%
Net margin
14.7%
FCF margin
16.7%
Return on equity
13.1%
Return on assets
7.8%

Growth

Growth. Compound annual growth: (end ÷ start)^(1 ÷ years) − 1, both ends positive.
Metric1y3y CAGR5y CAGR9y CAGR
Revenueup 5.67%up 0.51%up 5.08%—
EPS (diluted)down 51.31%down 1.65%up 8.27%up 16.51%
Free cash flowup 16.44%down 1.78%up 5.26%up 15.12%
Change in share count
0.00%

Financial strength

Current ratio
1.58×
Debt / equity
0.25×
Net debt
$4.41B
Interest coverage
16.3×
Equity / assets
60.1%

Shareholder returns

Dividends per share
$2.40
Dividends paid
$4.12B
Buybacks
$893M
Payout ratio
63.1%
Stock comp. / revenue
1.5%
Piotroski F-Score · Altman Z''-Score

Quality screens

Piotroski F-Score

6 of 9 checks passed

FY2025 vs FY2024

  • PassPositive return on assets8.0%
  • PassPositive operating cash flow$9.57B
  • FailReturn on assets improved8.0% vs 18.3%
  • PassOperating cash flow above net income11.7% vs 8.0%
  • PassLong-term debt / assets fell11.4% vs 15.5%
  • FailCurrent ratio improved1.58× vs 1.67×
  • PassNo increase in share count1.75B vs 1.75B
  • PassGross margin improved56.4% vs 55.4%
  • FailAsset turnover improved0.54× vs 0.57×

Altman Z''-Score

Needs current assets and liabilities, retained earnings, operating income, total assets, liabilities and equity from the latest 10-K.

Screening heuristic, not a recommendation. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

Last 10 fiscal years · newest first

Financial statements

USD millions, except per-share figures (USD). Share counts in millions.

Income statement

Income statement. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Revenue44,32841,95040,10943,65343,07534,60831,90430,57827,39020,853
YoY (Revenue)+5.67%+4.59%-8.12%+1.34%+24.47%+8.48%+4.34%—+31.35%—
Gross profit25,00923,24422,13424,51124,53819,60518,67317,872——
Research & development2,9422,8442,7412,8882,7422,4202,440———
Selling, general & admin.12,33211,69710,94911,24811,3249,6969,7659,7449,1176,672
Operating income8,0536,8256,4788,3628,4255,3574,5323,6501,7263,185
Interest expense493559637558533546670826904431
Pretax income8,4667,0136,6648,3068,2114,9684,0772,8732,2311,413
Income tax1,942-6,3899411,3731,1404973905391,878350
Net income6,52413,4025,7236,9337,0714,4953,6872,3684771,400
YoY (Net income)-51.32%+134.18%-17.45%-1.95%+57.31%+21.91%+55.70%+396.44%-65.93%—
EPS (basic)3.737.673.283.943.972.522.071.340.270.94
EPS (diluted)3.727.643.263.913.942.502.061.330.270.94
YoY (EPS (diluted))-51.31%+134.36%-16.62%-0.76%+57.60%+21.36%+54.89%+392.59%-71.28%—
Diluted shares (weighted)1,7481,7481,7491,7641,7891,7861,7811,7701,7491,483

Balance sheet

Balance sheet. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Cash & equivalents8,5227,6166,8969,8829,7996,8383,8603,8449,40718,620
Receivables7,9296,9256,5656,2186,4876,4145,4255,1825,2493,248
Inventory6,4886,1946,5706,1735,1575,0124,3163,7963,6012,434
Current assets25,99623,65622,67025,22424,23920,44115,66714,63220,14726,776
Goodwill24,03523,10823,67922,79923,23123,74423,19523,25424,0207,683
Intangible assets5,5266,6478,81510,45412,73914,78417,02518,94221,4734,539
Total assets86,71381,41473,21474,43875,19672,54867,88767,17376,25052,666
Current liabilities16,49614,15713,84115,48913,10511,90710,8639,0128,9126,660
Short-term debt3,0331,5001,0802,2517542201,4782077141,325
Long-term debt9,89612,62513,59914,52217,29618,52716,66119,35927,21020,681
Retained earnings49,78147,26137,55435,25731,52827,62725,84724,56023,97825,565
Stockholders' equity52,13047,66438,60336,68635,80232,78431,08830,52430,89720,538
Shares outstanding1,7381,7341,7351,7381,7631,7721,7631,7561,7461,728

Cash flow

Cash flow. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Operating cash flow9,5668,5587,2619,58110,5337,9016,1366,3005,5703,203
Capital expenditures2,1712,2072,2021,7771,8852,1771,6381,3941,1351,121
Free cash flow7,3956,3515,0597,8048,6485,7244,4984,9064,4352,082
YoY (Free cash flow)+16.44%+25.54%-35.17%-9.76%+51.08%+27.26%-8.32%+10.62%+113.02%—
Stock-based compensation664673644685640546519477406310
Share repurchases8931,2951,2273,7952,299403718238117522
Dividends paid4,1163,8363,5563,3093,2022,5602,2701,9741,8491,539
Dividends per share2.402.24————————
Key financials (annual, 10-K)

Values as reported in each fiscal year's Form 10-K (XBRL data on SEC EDGAR); growth and ratios are computed from those values. Revenue is the total revenue figure the company tagged (omitted when the only figure tagged is evidently partial, e.g. below net income); growth is only shown between consecutive ~12-month fiscal years reported with the same revenue measure. Per-share figures and share counts are as reported and not adjusted for later stock splits. — = not reported.

FY2025 · per diluted weighted share

Per share and valuation context

EPS (diluted)
$3.72
Revenue per share
$25.36
FCF per share
$4.23
Book value per share
$29.82
Tangible book per share
$12.91
Cash per share
$4.88
Dividends per share
$2.40
Public floatas of Jun 30, 2025
$232B

Price ratios need a live quote. This page shows no stock prices. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

Price ratio calculator

Type a share price to compute ratios from the latest 10-K figures. Nothing is stored or sent. (FY2025)

Market capPrice × diluted weighted shares
—
P/EPrice ÷ diluted EPS
—
P/BPrice ÷ book value per share
—
P/SPrice ÷ revenue per share
—
P/FCFPrice ÷ FCF per share
—
Dividend yieldDividends per share ÷ price
—
SEC EDGAR

Filing timeline

  1. 8-K
    Current report· Oct 21, 2026(SEC EDGAR)
    • 8.01Other events
    • 9.01Financial statements and exhibits
  2. 8-K
    Current report· Oct 21, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 9.01Financial statements and exhibits
  3. 8-K
    Current report· Aug 20, 2026(SEC EDGAR)
    • 7.01Regulation FD disclosure
    • 8.01Other events
    • 9.01Financial statements and exhibits
  4. 10-Q
    Quarterly report· Jun 30, 2026(SEC EDGAR)
  5. 8-K
    Current report· Jul 16, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 9.01Financial statements and exhibits
  6. 10-Q
    Quarterly report· Mar 31, 2026(SEC EDGAR)
  7. 8-K
    Current report· Apr 24, 2026(SEC EDGAR)
    • 5.02Officer or director changes
    • 5.03Bylaws or fiscal year change
    • 5.07Shareholder vote results
    • 9.01Financial statements and exhibits
  8. 8-K
    Current report· Apr 10, 2026(SEC EDGAR)
    • 8.01Other events
    • 9.01Financial statements and exhibits
  9. 8-K
    Current report· Apr 16, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 9.01Financial statements and exhibits
  10. 8-K
    Current report· Mar 23, 2026(SEC EDGAR)
    • 8.01Other events
    • 9.01Financial statements and exhibits
All filings on SEC EDGAR
SIC 2834 · Pharmaceutical Preparations

Peers (same SIC code)

Peers (same SIC code)
TickerRevenue (FY)YoYNet marginROEF-Score5y revenue
JNJJOHNSON & JOHNSON$94.2B—28.5%———
LLYELI LILLY & Co$65.2B—31.7%———
MRKMerck & Co., Inc.$65B—28.1%———
PFEPFIZER INC$62.6Bdown 1.65%12.4%8.9%6/9
ABBVAbbVie Inc.$61.2B—6.9%———
ABTABBOTT LABORATORIES (This company)$44.3Bup 5.67%14.7%13.1%6/9
NVSNOVARTIS AG——————
AZNASTRAZENECA PLC——————
NVONOVO NORDISK A S——————
Peer median$65Bdown 1.65%28.1%8.9%6/9—

Companies with the same 4-digit SIC code, ordered by latest revenue. The median excludes this company. — = not reported or not computable.

Frequently asked questions

What does ABBOTT LABORATORIES do?

The SEC classifies ABBOTT LABORATORIES under Standard Industrial Classification (SIC) code 2834, "Pharmaceutical Preparations". It is headquartered in Abbott Park, IL. It is incorporated in IL. In fiscal 2025 it reported revenue of $44.33B and net income of $6.52B in its annual 10-K report.

What was ABBOTT LABORATORIES's revenue in 2025?

ABBOTT LABORATORIES reported revenue of $44.33B for fiscal 2025, which ended Dec 31, 2025, up 5.7% from $41.95B in fiscal 2024, according to its annual 10-K report filed with the SEC on Feb 20, 2026.

What was ABBOTT LABORATORIES's net income in 2025?

ABBOTT LABORATORIES reported net income of $6.52B for fiscal 2025, a net margin of 14.7% of revenue.

Where is ABBOTT LABORATORIES listed?

According to the SEC, ABBOTT LABORATORIES's ticker ABT is listed on NYSE.

When does ABBOTT LABORATORIES's fiscal year end?

According to the SEC, ABBOTT LABORATORIES's fiscal year ends on December 31; its latest reported fiscal year (2025) ended Dec 31, 2025.

Source: SEC EDGAR · Last updated:

Ver en español

Not investment advice: This page shows financial data that companies reported to the US Securities and Exchange Commission, for information only. It is not investment advice or a recommendation to buy or sell any security, and it shows no stock prices. Data may be incomplete, restated or out of date — check the original filings on SEC EDGAR before making decisions.